Poltreg Past Earnings Performance
Past criteria checks 0/6
Poltreg's earnings have been declining at an average annual rate of -64.4%, while the Biotechs industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 14% per year.
Key information
-64.4%
Earnings growth rate
-52.6%
EPS growth rate
| Biotechs Industry Growth | 56.3% |
| Revenue growth rate | 14.0% |
| Return on equity | -18.6% |
| Net Margin | -1,738.6% |
| Next Earnings Update | 12 Sep 2024 |
Recent past performance updates
Recent updates
Is Poltreg (WSE:PTG) In A Good Position To Invest In Growth?
Mar 13
Here's Why We're Not Too Worried About Poltreg's (WSE:PTG) Cash Burn Situation
Jun 21We Think Poltreg (WSE:PTG) Can Afford To Drive Business Growth
Oct 05Here's Why We're Not Too Worried About Poltreg's (WSE:PTG) Cash Burn Situation
Jun 16Poltreg (WSE:PTG) Is In A Good Position To Deliver On Growth Plans
Feb 24Revenue & Expenses Breakdown
How Poltreg makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1 | -16 | 15 | 0 |
| 31 Dec 23 | 1 | -14 | 16 | 0 |
| 30 Sep 23 | 1 | -10 | 15 | 0 |
| 30 Jun 23 | 1 | -5 | 12 | 0 |
| 31 Mar 23 | 1 | -2 | 9 | 0 |
| 31 Dec 22 | 1 | -2 | 7 | 0 |
| 30 Sep 22 | 1 | -4 | 8 | 0 |
| 30 Jun 22 | 1 | -4 | 8 | 0 |
| 31 Mar 22 | 1 | -4 | 7 | 0 |
| 31 Dec 21 | 1 | -4 | 6 | 0 |
| 30 Sep 21 | 1 | -2 | 4 | 0 |
| 30 Jun 21 | 1 | -1 | 3 | 0 |
| 31 Mar 21 | 1 | -1 | 3 | 0 |
| 31 Dec 20 | 1 | -1 | 3 | 0 |
| 31 Dec 19 | 1 | -1 | 2 | 0 |
Quality Earnings: PTG is currently unprofitable.
Growing Profit Margin: PTG is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PTG is unprofitable, and losses have increased over the past 5 years at a rate of 64.4% per year.
Accelerating Growth: Unable to compare PTG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PTG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: PTG has a negative Return on Equity (-18.57%), as it is currently unprofitable.